Views

CrossRef citations to date

Altmetric

Letters to the Editor

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Heinz LudwigWilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Correspondence[email protected]

Meletios A. DimopoulosSchool of Medicine, National and Kapodistrian University of Athens, Athens, Greece;

Philippe MoreauUniversity of Nantes, Nantes, France;

Wee-Joo ChngNational University Cancer Institute, Singapore; ;National University Health System, Singapore; ;Cancer Science Institute, Singapore; ;National University of Singapore, Singapore;

Hartmut GoldschmidtHeidelberg Medical University, Heidelberg, Germany;

Roman HájekUniversity Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;

Thierry FaconCHRU Lille Hôpital Claude Huriez, Lille, France;

Ludek PourUniversity Hospital Brno, Brno, Czech Republic;

Ruben NiesvizkyWeill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA;

Albert OriolInstitut Català d’Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain;

Laura RosiñolHospital Clínic de Barcelona, Barcelona, Spain;

Aleksandr SuvorovFirst Republican Clinical Hospital of Udmurtia, Izhevsk, Russia;

Gianluca GaidanoDepartment of Translational Medicine, University of Eastern Piedmont, Novara, Italy;

Tomas PikaUniversity Hospital Olomouc, Olomouc, Czech Republic;

Katja WeiselUniversitatsklinikum Tubingen, Tubingen, Germany;

Vesselina Goranova-MarinovaUniversity Multiprofile Hospital for Active Treatment “Sv. Georgi” and Medical University, Plovdiv, Bulgaria;

Antonio PalumboUniversity of Torino, Torino, Italy;

Heidi H. GillenwaterOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;

Nehal MohamedOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;

Sanjay AggarwalOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;

Shibao FengOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;

Douglas JoshuaRoyal Prince Alfred Hospital, Camperdown, New South Wales, Australia

show all

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

ICMJE Form for Disclosure of Potential Conflicts of Interest

Disclosure of Interest

Supplemental Table 2: Responses by Age Subgroup

Supplemental Table 1: Patient Demographics and Baseline Disease Characteristics

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

ICMJE Form for Disclosure of Potential Conflicts of Interest

Disclosure of Interest

Supplemental Table 2: Responses by Age Subgroup

Supplemental Table 1: Patient Demographics and Baseline Disease Characteristics

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date